Metabolic Dysfunction-Associated Fatty Liver Disease Increases the Risk of Gastroesophageal Reflux Symptoms

References

• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. doi:10.1007/s12072-020-10094-2
   PubMed Web of Science ®Google Scholar
• Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1943. doi:10.1111/j.1572-0241.2006.00630.x
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. doi:10.1136/gutjnl-2012-304269
   PubMed Web of Science ®Google Scholar
• Ronkainen J, Agréus L. Epidemiology of reflux symptoms and GORD. Best Pract Res Clin Gastroenterol. 2013;27(3):325–337. doi:10.1016/j.bpg.2013.06.008
   Web of Science ®Google Scholar
• Drahos J, Ricker W, Parsons R, Pfeiffer RM, Warren JL, Cook MB. Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-medicare data. J Clin Gastroenterol. 2015;49(4):282–288. doi:10.1097/MCG.0000000000000119
   PubMed Web of Science ®Google Scholar
• Niigaki M, Adachi K, Hirakawa K, Furuta K, Kinoshita Y. Association between metabolic syndrome and prevalence of gastroesophageal reflux disease in a health screening facility in Japan. J Gastroenterol. 2013;48(4):463–472. doi:10.1007/s00535-012-0671-3
   Web of Science ®Google Scholar
• Kallel L, Bibani N, Fekih M, et al. Metabolic syndrome is associated with gastroesophageal reflux disease based on a 24-hour ambulatory pH monitoring. Dis Esophagus. 2011;24(3):153–159. doi:10.1111/j.1442-2050.2010.01118.x
   Web of Science ®Google Scholar
• Chung SJ, Kim D, Park MJ, et al. Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups. Gut. 2008;57(10):1360–1365. doi:10.1136/gut.2007.147090
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease and metabolic syndrome: shared genetic basis of pathogenesis. Hepatology. 2016;64(5):1417–1420. doi:10.1002/hep.28746
   PubMed Web of Science ®Google Scholar
• Choi JS, Kim HM, Yang YJ, Lee S, Jeong SH, Han KJ. Fatty liver disease and the risk of erosive oesophagitis in the Korean population: a cross-sectional study. BMJ Open. 2019;9(1):e023585. doi:10.1136/bmjopen-2018-023585
   PubMed Web of Science ®Google Scholar
• Min YW, Kim Y, Gwak GY, et al. Non-alcoholic fatty liver disease and the development of reflux esophagitis: a cohort study. J Gastroenterol Hepatol. 2018;33(5):1053–1058. doi:10.1111/jgh.14042
   PubMed Web of Science ®Google Scholar
• Yang HJ, Chang Y, Park SK, et al. Nonalcoholic fatty liver disease is associated with increased risk of reflux esophagitis. Dig Dis Sci. 2017;62(12):3605–3613. doi:10.1007/s10620-017-4805-6
   PubMed Web of Science ®Google Scholar
• Hung WC, Wu JS, Sun ZJ, Lu FH, Yang YC, Chang CJ. Gender differences in the association of non-alcoholic fatty liver disease and metabolic syndrome with erosive oesophagitis: a cross-sectional study in a Taiwanese population. BMJ Open. 2016;6(11):e013106. doi:10.1136/bmjopen-2016-013106
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Eguchi Y, Fukumori N, et al. The symptoms of gastroesophageal reflux disease correlate with high body mass index, the aspartate aminotransferase/alanine aminotransferase ratio and insulin resistance in Japanese patients with non-alcoholic fatty liver disease. Intern Med. 2015;54(24):3099–3104. doi:10.2169/internalmedicine.54.4297
   Web of Science ®Google Scholar
• Hung WC, Wu JS, Yang YC, Sun ZJ, Lu FH, Chang CJ. Nonalcoholic fatty liver disease vs. obesity on the risk of erosive oesophagitis. Eur J Clin Invest. 2014;44(12):1143–1149. doi:10.1111/eci.12348
   PubMed Web of Science ®Google Scholar
• Catanzaro R, Calabrese F, Occhipinti S, et al. Nonalcoholic fatty liver disease increases risk for gastroesophageal reflux symptoms. Dig Dis Sci. 2014;59(8):1939–1945. doi:10.1007/s10620-014-3113-7
   Web of Science ®Google Scholar
• Miele L, Cammarota G, Vero V, et al. Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis. 2012;44(12):1032–1036. doi:10.1016/j.dld.2012.08.005
   Google Scholar
• Fujikawa Y, Tominaga K, Fujii H, et al. High prevalence of gastroesophageal reflux symptoms in patients with non-alcoholic fatty liver disease associated with serum levels of triglyceride and cholesterol but not simple visceral obesity. Digestion. 2012;86(3):228–237. doi:10.1159/000341418
   Web of Science ®Google Scholar
• Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30(10):1030–1038. doi:10.1111/j.1365-2036.2009.04142.x
   PubMed Web of Science ®Google Scholar
• Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59(6):714–721. doi:10.1136/gut.2009.200063
   PubMed Web of Science ®Google Scholar
• Lacy BE, Chehade R, Crowell MD. A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11). Am J Gastroenterol. 2011;106(9):1604–1611. doi:10.1038/ajg.2011.180
   Web of Science ®Google Scholar
• Jonasson C, Wernersson B, Hoff DA, Hatlebakk JG. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;37(5):564–572. doi:10.1111/apt.12204
   PubMed Web of Science ®Google Scholar
• Suzuki H, Matsuzaki J, Okada S, Hirata K, Fukuhara S, Hibi T. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United Eur Gastroenterol J. 2013;1(3):175–183. doi:10.1177/2050640613485238
   PubMed Web of Science ®Google Scholar
• Zavala-Gonzales MA, Azamar-Jacome AA, Meixueiro-Daza A, et al. Validation and diagnostic usefulness of gastroesophageal reflux disease questionnaire in a primary care level in Mexico. J Neurogastroenterol Motil. 2014;20(4):475–482. doi:10.5056/jnm14014
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi:10.1111/j.1600-0447.1983.tb09716.x
   PubMed Web of Science ®Google Scholar
• Turon H, Carey M, Boyes A, Hobden B, Dilworth S, Sanson-Fisher R. Agreement between a single-item measure of anxiety and depression and the hospital anxiety and depression scale: a cross-sectional study. PLoS One. 2019;14(1):e0210111. doi:10.1371/journal.pone.0210111
   PubMed Web of Science ®Google Scholar
• Wondie Y, Mehnert A, Hinz A, Frey R. The Hospital Anxiety and Depression Scale (HADS) applied to Ethiopian cancer patients. PLoS One. 2020;15(12):e0243357. doi:10.1371/journal.pone.0243357
   PubMed Web of Science ®Google Scholar
• Westhoff-Bleck M, Winter L, Aguirre Davila L, et al. Diagnostic evaluation of the hospital depression scale (HADS) and the Beck depression inventory II (BDI-II) in adults with congenital heart disease using a structured clinical interview: impact of depression severity. Eur J Prev Cardiol. 2020;27(4):381–390. doi:10.1177/2047487319865055
   Web of Science ®Google Scholar
• Yue T, Li Q, Wang R, et al. Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in evaluating anxiety and depression in patients with psoriatic arthritis. Dermatology. 2020;236(2):170–178. doi:10.1159/000498848
   PubMed Web of Science ®Google Scholar
• Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–253.
   PubMed Web of Science ®Google Scholar
• Sun W, Zhang D, Sun J, et al. Association between non-alcoholic fatty liver disease and autonomic dysfunction in a Chinese population. QJM. 2015;108(8):617–624. doi:10.1093/qjmed/hcv006
   Web of Science ®Google Scholar
• Sabath E, Báez-Ruiz A, Buijs RM. Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. Obes Rev. 2015;16(10):871–882. doi:10.1111/obr.12308
   Web of Science ®Google Scholar
• Gehrke N, Schattenberg JM. Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology. 2020;158(7):1929–1947.e6.
   PubMed Web of Science ®Google Scholar
• Jorge ASB, Andrade JMO, Paraíso AF, et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obes Res Clin Pract. 2018;12(Suppl 2):1–8. doi:10.1016/j.orcp.2016.03.009
   PubMed Web of Science ®Google Scholar
• Nelson JE, Handa P, Aouizerat B, et al. Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Aliment Pharmacol Ther. 2016;44(11–12):1253–1264. doi:10.1111/apt.13824
   Web of Science ®Google Scholar
• Rieder F, Biancani P, Harnett K, Yerian L, Falk GW. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G571–G581. doi:10.1152/ajpgi.00454.2009
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen M, Wu J, et al. Improved control of hypertension following laparoscopic fundoplication for gastroesophageal reflux disease. Front Med. 2017;11(1):68–73. doi:10.1007/s11684-016-0490-7
   Web of Science ®Google Scholar
• Li ZT, Ji F, Han XW, Wang L, Yue YQ, Wang ZG. The role of gastroesophageal reflux in provoking high blood pressure episodes in patients with hypertension. J Clin Gastroenterol. 2018;52(8):685–690.
   Web of Science ®Google Scholar
• Oh C, Youn JK, Han JW, Kim HY, Jung SE. Analysis of growth, nutritional status and hospital visitation scores associated with reflux after nissen fundoplication in neurologically impaired children with gastroesophageal reflux. World J Surg. 2018;42(5):1463–1468. doi:10.1007/s00268-017-4276-0
   Web of Science ®Google Scholar